Clinical Trial Update: Imexon for Relapsed Follicular and Aggressive Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial results for imexon in relapsed follicular lymphoma and various aggressive B-cell lymphomas have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Imexon (imexon)

Snippet

Sponsor: University of Rochester | Conditions: Follicular Lymphoma, Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-07-01